We are live on ! Find out more
TGI

TRV GP III Portfolio holdings

AUM $6.14M
1-Year Est. Return 45.44%
This Fund
S&P 500
This Quarter Est. Return
+28.75%
1 Year Est. Return
+45.44%
3 Year Est. Return
+169.98%
5 Year Est. Return
+802.39%
10 Year Est. Return
–
AUM
$278M
AUM Growth
-$7.82M
Cap. Flow
-$70.3M
Cap. Flow %
-25.3%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$42.4M
2
EDIT icon
Editas Medicine
EDIT
+$27.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
1
Voyager Therapeutics
VYGR
$189M
$176M 63.52%
9,391,176
– –
JNCE
2
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$68.1M 24.53%
3,048,780
– –
MYOK
3
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$33.2M 11.95%
680,272
-816,326
-55% -$42.4M
EDIT icon
4
Editas Medicine
EDIT
$445M
– –
-906,176
Closed -$27.8M

Similar funds

TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

TRV GP III's Q1 2018 Portfolio in Review

As of Q1 2018, TRV GP III held 4 positions worth $278M, down 2.7% from $286M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP III withdrew a net $70.3M in Q1 2018, closing 1 position and reducing 1 holding. Its most notable exit was Editas Medicine, an estimated $27.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP III's biggest Q1 2018 reduction was MyoKardia, Inc. Common Stock, cutting an estimated $42.4M.
  • TRV GP III fully exited Editas Medicine in Q1 2018, selling an estimated $27.8M.
  • TRV GP III's ten largest holdings make up 100% of its $278M portfolio in Q1 2018.
  • TRV GP III opened 0 new positions and closed 1 in Q1 2018.
  • TRV GP III's portfolio value fell 2.7% quarter-over-quarter to $278M.

Based on TRV GP III's 13F filing for Q1 2018, filed 19 Apr 2018.